Acadian Asset Management
TRPX

Acadian Asset Management’s Therapix Biosciences Ltd. TRPX Stock Holding History

Acadian Asset Management’s Portfolio TRPX Stock Details TRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,100
Closed -$23K – 1919
2018
Q1 		$23K Hold
4,100
– – ﹤0.01% 1474
2017
Q4 		$22K Buy
+4,100
New +$21.9K ﹤0.01% 1358

Other funds holding TRPX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acadian Asset Management's TRPX Position: Q2 2018 in Review

Acadian Asset Management sold out of Therapix Biosciences Ltd. (TRPX) in Q2 2018, closing a stake of 4,100 shares — an estimated $23K sold.

Acadian Asset Management first reported a position in TRPX in Q4 2017 and held it in 2 quarters. The position peaked at $23K in Q1 2018. 4 funds tracked by Wall St. Rank hold TRPX as of Q2 2018.

  • Acadian Asset Management reported no remaining Therapix Biosciences Ltd. position as of Q2 2018 after selling out during the quarter.
  • Acadian Asset Management sold 4,100 Therapix Biosciences Ltd. shares in Q2 2018, an estimated $23K.
  • Acadian Asset Management first reported a position in Therapix Biosciences Ltd. in Q4 2017 and held it in 2 quarters.
  • Acadian Asset Management's Therapix Biosciences Ltd. position peaked at $23K in Q1 2018.
  • 4 funds tracked by Wall St. Rank held Therapix Biosciences Ltd. as of Q2 2018.

Based on Acadian Asset Management's 13F filing for Q2 2018, filed 24 Jul 2018.